Pediatric And Rare Disease Drug Development Legislation Clears US House Committee

As amended, the Give Kids A Chance Act would renew the rare pediatric disease voucher program for five years and give the FDA new authority to bring enforcement action when pediatric studies are overdue. However, it would not remove the exemption from pediatric study requirements for non-cancer orphan drugs, which Democrats had sought. 

Gift packaging
A bipartisan package of measures targeting rare and pediatric disease drug development cleared a House committee. • Source: Shutterstock

Legislation to spur development of treatments for pediatric and rare diseases easily cleared a US House committee on 18 September, boosting chances for inclusion in an end-of-year omnibus package.

An amended version of the Give Kids A Chance Act of 2024 (H.R. 3433) advanced out of the House...

More from Legislation

More from Pink Sheet

Recent And Upcoming FDA Advisory Committee Meetings

 
• By 

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.

UK-Wide Strategy Needed To Move Clinical Trial Diversity Plans To Next Stage

 
• By 

The UK’s research-based pharma industry and medical research charities have set out clear action points to drive greater diversity and inclusion in clinical trials.

Blenrep’s Comeback Continues As England Becomes First To Fund Drug

 

Blenrep, GSK’s multiple myeloma therapy, faced a major setback when it was withdrawn from the market in 2022. The drug has since made a return as a second-line therapy, and is on track to being reimbursed in England.